within Pharmacolibrary.Drugs.ATC.M;

model M01CB04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666668e-07,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01CB04</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Aurothioglucose is a gold-containing compound formerly used as a disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis. It is administered via intramuscular injection and acts by modulating immune responses, but its use has greatly diminished due to safety concerns and the advent of more effective agents. It is not commonly used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not well characterized in recent literature. Existing reports suggest a one-compartment model after intramuscular administration in adults with rheumatoid arthritis.</p><h4>References</h4><ol><li><p>Blocka, KL, et al., &amp; Furst, DE (1986). Clinical pharmacokinetics of oral and injectable gold compounds. <i>Clinical pharmacokinetics</i> 11(2) 133–143. DOI:<a href=\"https://doi.org/10.2165/00003088-198611020-00003\">10.2165/00003088-198611020-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3082559/\">https://pubmed.ncbi.nlm.nih.gov/3082559</a></p></li><li><p>Furst, DE (1983). Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> 3(5) 284–298. DOI:<a href=\"https://doi.org/10.1002/j.1875-9114.1983.tb03277.x\">10.1002/j.1875-9114.1983.tb03277.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6417628/\">https://pubmed.ncbi.nlm.nih.gov/6417628</a></p></li><li><p>Blocka, K (1983). Auranofin versus injectable gold. Comparison of pharmacokinetic properties. <i>The American journal of medicine</i> 75(6A) 114–122. DOI:<a href=\"https://doi.org/10.1016/0002-9343(83)90483-7\">10.1016/0002-9343(83)90483-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6419592/\">https://pubmed.ncbi.nlm.nih.gov/6419592</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01CB04;
